Publication

Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: A systematic review and meta-analysis

Koleva-Kolarova, R. G., Oktora, M. P., Robijn, A. L., Greuter, M. J. W., Reyners, A. K. L., Buskens, E. & de Bock, G. H., Apr-2017, In : CANCER TREATMENT REVIEWS. 55, p. 16-25 10 p.

Research output: Contribution to journalReview articleAcademicpeer-review

APA

Koleva-Kolarova, R. G., Oktora, M. P., Robijn, A. L., Greuter, M. J. W., Reyners, A. K. L., Buskens, E., & de Bock, G. H. (2017). Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: A systematic review and meta-analysis. CANCER TREATMENT REVIEWS, 55, 16-25. https://doi.org/10.1016/j.ctrv.2017.01.001

Author

Koleva-Kolarova, Rositsa G. ; Oktora, Monika P. ; Robijn, Annelies L. ; Greuter, Marcel J. W. ; Reyners, Anna K. L. ; Buskens, Erik ; de Bock, Geertruida H. / Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer : A systematic review and meta-analysis. In: CANCER TREATMENT REVIEWS. 2017 ; Vol. 55. pp. 16-25.

Harvard

Koleva-Kolarova, RG, Oktora, MP, Robijn, AL, Greuter, MJW, Reyners, AKL, Buskens, E & de Bock, GH 2017, 'Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: A systematic review and meta-analysis', CANCER TREATMENT REVIEWS, vol. 55, pp. 16-25. https://doi.org/10.1016/j.ctrv.2017.01.001

Standard

Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer : A systematic review and meta-analysis. / Koleva-Kolarova, Rositsa G.; Oktora, Monika P.; Robijn, Annelies L.; Greuter, Marcel J. W.; Reyners, Anna K. L.; Buskens, Erik; de Bock, Geertruida H.

In: CANCER TREATMENT REVIEWS, Vol. 55, 04.2017, p. 16-25.

Research output: Contribution to journalReview articleAcademicpeer-review

Vancouver

Koleva-Kolarova RG, Oktora MP, Robijn AL, Greuter MJW, Reyners AKL, Buskens E et al. Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: A systematic review and meta-analysis. CANCER TREATMENT REVIEWS. 2017 Apr;55:16-25. https://doi.org/10.1016/j.ctrv.2017.01.001


BibTeX

@article{ff79ae20847343f8aa3603535bd5ce4e,
title = "Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: A systematic review and meta-analysis",
abstract = "This article aimed to assess the clinical effectiveness of non-hormonal targeted therapies (TTs) in terms of increase of median progression-free survival (PFS) and overall survival (OS) in receptor-positive metastatic breast cancer (MBC) patients by performing a systematic review and meta-analysis. We systematically searched relevant randomized controlled trials and extracted data about number of patients on targeted and comparator therapy, receptor status, line of treatment, median PFS and OS, p values, hazard ratios (HRs) and 95{\%} confidence intervals (CI). Inverse variance was used to estimate pooled HRs, chi-square test for heterogeneity and Jadad scale for quality were applied. Thirty-eight studies (n = 17,192 patients) were eligible for inclusion. TTs added 3.3 months to the median PFS [0.7-9.6; HRs 0.74, 95{\%} CI 0.71-0.77] of receptor-positive MBC patients and prolonged their median OS with 3.5 months [0-4.7; HRs 0.90, 95{\%} CI 0.82-0.98]. The highest increase in median PFS of 3.6 months was found in HER2-/hormone receptor(HR)+ patients, while the highest increase in median OS of 7.2 months was observed in HER2+/HRmixed status patients. First-line ITs were most effective in increasing the median PFS in the HR+/HER2- group with 2.0 months, and in the HER2+/HRmixed group by adding 4.7 months to the median OS. Second-line TTs were most effective for HER2-/HR+ patients by adding 2.6 months to their PFS, and for HER2+/HRmixed patients by adding 3.1 months to their median OS. Albeit small, the gain in months of median PFS and median OS was significant. Importantly, the results reported show large variation, and thus routinely applying a personalized approach seems warranted. (C) 2017 Elsevier Ltd. All rights reserved.",
keywords = "Breast neoplasm, Molecular targeted therapy, Human epidermal growth factor receptor 2, Estrogen receptors, Progesterone receptors, Survival analysis, GROWTH-FACTOR RECEPTOR, PHASE-III TRIAL, LAPATINIB PLUS CAPECITABINE, 1ST-LINE TREATMENT, DOUBLE-BLIND, OPEN-LABEL, TRASTUZUMAB EMTANSINE, SURVIVAL ANALYSIS, RANDOMIZED-TRIAL, 2ND-LINE TREATMENT",
author = "Koleva-Kolarova, {Rositsa G.} and Oktora, {Monika P.} and Robijn, {Annelies L.} and Greuter, {Marcel J. W.} and Reyners, {Anna K. L.} and Erik Buskens and {de Bock}, {Geertruida H.}",
note = "Copyright {\circledC} 2017 Elsevier Ltd. All rights reserved.",
year = "2017",
month = "4",
doi = "10.1016/j.ctrv.2017.01.001",
language = "English",
volume = "55",
pages = "16--25",
journal = "CANCER TREATMENT REVIEWS",
issn = "0305-7372",
publisher = "ELSEVIER SCI LTD",

}

RIS

TY - JOUR

T1 - Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer

T2 - A systematic review and meta-analysis

AU - Koleva-Kolarova, Rositsa G.

AU - Oktora, Monika P.

AU - Robijn, Annelies L.

AU - Greuter, Marcel J. W.

AU - Reyners, Anna K. L.

AU - Buskens, Erik

AU - de Bock, Geertruida H.

N1 - Copyright © 2017 Elsevier Ltd. All rights reserved.

PY - 2017/4

Y1 - 2017/4

N2 - This article aimed to assess the clinical effectiveness of non-hormonal targeted therapies (TTs) in terms of increase of median progression-free survival (PFS) and overall survival (OS) in receptor-positive metastatic breast cancer (MBC) patients by performing a systematic review and meta-analysis. We systematically searched relevant randomized controlled trials and extracted data about number of patients on targeted and comparator therapy, receptor status, line of treatment, median PFS and OS, p values, hazard ratios (HRs) and 95% confidence intervals (CI). Inverse variance was used to estimate pooled HRs, chi-square test for heterogeneity and Jadad scale for quality were applied. Thirty-eight studies (n = 17,192 patients) were eligible for inclusion. TTs added 3.3 months to the median PFS [0.7-9.6; HRs 0.74, 95% CI 0.71-0.77] of receptor-positive MBC patients and prolonged their median OS with 3.5 months [0-4.7; HRs 0.90, 95% CI 0.82-0.98]. The highest increase in median PFS of 3.6 months was found in HER2-/hormone receptor(HR)+ patients, while the highest increase in median OS of 7.2 months was observed in HER2+/HRmixed status patients. First-line ITs were most effective in increasing the median PFS in the HR+/HER2- group with 2.0 months, and in the HER2+/HRmixed group by adding 4.7 months to the median OS. Second-line TTs were most effective for HER2-/HR+ patients by adding 2.6 months to their PFS, and for HER2+/HRmixed patients by adding 3.1 months to their median OS. Albeit small, the gain in months of median PFS and median OS was significant. Importantly, the results reported show large variation, and thus routinely applying a personalized approach seems warranted. (C) 2017 Elsevier Ltd. All rights reserved.

AB - This article aimed to assess the clinical effectiveness of non-hormonal targeted therapies (TTs) in terms of increase of median progression-free survival (PFS) and overall survival (OS) in receptor-positive metastatic breast cancer (MBC) patients by performing a systematic review and meta-analysis. We systematically searched relevant randomized controlled trials and extracted data about number of patients on targeted and comparator therapy, receptor status, line of treatment, median PFS and OS, p values, hazard ratios (HRs) and 95% confidence intervals (CI). Inverse variance was used to estimate pooled HRs, chi-square test for heterogeneity and Jadad scale for quality were applied. Thirty-eight studies (n = 17,192 patients) were eligible for inclusion. TTs added 3.3 months to the median PFS [0.7-9.6; HRs 0.74, 95% CI 0.71-0.77] of receptor-positive MBC patients and prolonged their median OS with 3.5 months [0-4.7; HRs 0.90, 95% CI 0.82-0.98]. The highest increase in median PFS of 3.6 months was found in HER2-/hormone receptor(HR)+ patients, while the highest increase in median OS of 7.2 months was observed in HER2+/HRmixed status patients. First-line ITs were most effective in increasing the median PFS in the HR+/HER2- group with 2.0 months, and in the HER2+/HRmixed group by adding 4.7 months to the median OS. Second-line TTs were most effective for HER2-/HR+ patients by adding 2.6 months to their PFS, and for HER2+/HRmixed patients by adding 3.1 months to their median OS. Albeit small, the gain in months of median PFS and median OS was significant. Importantly, the results reported show large variation, and thus routinely applying a personalized approach seems warranted. (C) 2017 Elsevier Ltd. All rights reserved.

KW - Breast neoplasm

KW - Molecular targeted therapy

KW - Human epidermal growth factor receptor 2

KW - Estrogen receptors

KW - Progesterone receptors

KW - Survival analysis

KW - GROWTH-FACTOR RECEPTOR

KW - PHASE-III TRIAL

KW - LAPATINIB PLUS CAPECITABINE

KW - 1ST-LINE TREATMENT

KW - DOUBLE-BLIND

KW - OPEN-LABEL

KW - TRASTUZUMAB EMTANSINE

KW - SURVIVAL ANALYSIS

KW - RANDOMIZED-TRIAL

KW - 2ND-LINE TREATMENT

U2 - 10.1016/j.ctrv.2017.01.001

DO - 10.1016/j.ctrv.2017.01.001

M3 - Review article

VL - 55

SP - 16

EP - 25

JO - CANCER TREATMENT REVIEWS

JF - CANCER TREATMENT REVIEWS

SN - 0305-7372

ER -

ID: 40417997